Implantica AG (IMP-A-SDB.ST)
SEK 26.85
(-5.95%)
SEK 26.85
(-5.95%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -23.74 Million EUR | -14.02% |
| 2022 | -20.82 Million EUR | -35.56% |
| 2021 | -15.36 Million EUR | -49.47% |
| 2020 | -10.27 Million EUR | -113.88% |
| 2019 | -4.8 Million EUR | -5.51% |
| 2018 | -4.55 Million EUR | -45.72% |
| 2017 | -3.12 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -6.37 Million EUR | -89.51% |
| 2024 Q1 | -3.36 Million EUR | 60.78% |
| 2023 Q1 | -4.55 Million EUR | 1.6% |
| 2023 FY | -23.74 Million EUR | -14.02% |
| 2023 Q4 | -8.57 Million EUR | -57.61% |
| 2023 Q3 | -5.44 Million EUR | -5.2% |
| 2023 Q2 | -5.17 Million EUR | -13.64% |
| 2022 Q4 | -4.62 Million EUR | 18.27% |
| 2022 Q3 | -5.66 Million EUR | 1.77% |
| 2022 Q2 | -5.76 Million EUR | -20.64% |
| 2022 FY | -20.82 Million EUR | -35.56% |
| 2022 Q1 | -4.77 Million EUR | 23.63% |
| 2021 Q3 | -4.26 Million EUR | -48.38% |
| 2021 Q2 | -2.87 Million EUR | -46.24% |
| 2021 Q1 | -1.96 Million EUR | 37.59% |
| 2021 Q4 | -6.25 Million EUR | -46.6% |
| 2021 FY | -15.36 Million EUR | -49.47% |
| 2020 FY | -10.27 Million EUR | -113.88% |
| 2020 Q2 | -1.14 Million EUR | 8.63% |
| 2020 Q4 | -3.15 Million EUR | 33.4% |
| 2020 Q3 | -4.73 Million EUR | -313.46% |
| 2020 Q1 | -1.25 Million EUR | -4.07% |
| 2019 Q3 | -815 Thousand EUR | 0.0% |
| 2019 Q4 | -1.2 Million EUR | -47.61% |
| 2019 FY | -4.8 Million EUR | -5.51% |
| 2018 FY | -4.55 Million EUR | -45.72% |
| 2017 FY | -3.12 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | 69.496% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 122.941% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 122.941% |
| Arcoma AB | 2.56 Million SEK | 1026.053% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 82.842% |
| BICO Group AB (publ) | -835.7 Million SEK | 97.159% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 195.063% |
| CellaVision AB (publ) | 130.3 Million SEK | 118.221% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | 70.243% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | 18.648% |
| C-Rad AB (publ) | 35.52 Million SEK | 166.83% |
| Duearity AB (publ) | -26.19 Million SEK | 9.339% |
| Dignitana AB (publ) | -17.36 Million SEK | -36.751% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 74.954% |
| Getinge AB (publ) | 2.41 Billion SEK | 100.984% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | 65.071% |
| Iconovo AB (publ) | -45.89 Million SEK | 48.263% |
| Integrum AB (publ) | 4.03 Million SEK | 688.819% |
| Luxbright AB (publ) | -25.37 Million SEK | 6.428% |
| Mentice AB (publ) | -2.81 Million SEK | -742.882% |
| OssDsign AB (publ) | -130.49 Million SEK | 81.804% |
| Paxman AB (publ) | 8.33 Million SEK | 385.042% |
| Promimic AB (publ) | -9.22 Million SEK | -157.471% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 85.156% |
| SciBase Holding AB (publ) | -55.58 Million SEK | 57.283% |
| ScandiDos AB (publ) | -14.64 Million SEK | -62.108% |
| Sectra AB (publ) | 428.38 Million SEK | 105.543% |
| Sedana Medical AB (publ) | -59.61 Million SEK | 60.169% |
| Senzime AB (publ) | -134.14 Million SEK | 82.3% |
| SpectraCure AB (publ) | -20.44 Million SEK | -16.159% |
| Stille AB | 26.64 Million SEK | 189.109% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 99.383% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 125.859% |